Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASTING: Ocrelizumab in RRMS
NCT02861014Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2016
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Roche. Started Sep 2016; status: completed.
02
Drugs
ocrelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02861014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02861014.